← Back to Screener
Journey Medical Corporation Common Stock (DERM)
Price$6.09
Value ScoreD
Growth ScoreB
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-32.24%
Price vs S&P 500 (4W)16.61%
VGM Score45.14
Market Capitalization$173.74M
All Metrics
Book Value / Share (Quarterly)$1.13
P/TBV (Annual)49.26x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-5.66%
Cash Flow / Share (Quarterly)$-0.25
Price vs S&P 500 (YTD)-29.09%
Gross Margin (TTM)65.44%
Net Profit Margin (TTM)-14.82%
EPS (TTM)$-0.38
10-Day Avg Trading Volume0.27M
EPS Excl Extra (TTM)$-0.38
Revenue Growth (5Y)6.79%
EPS (Annual)$-0.47
ROI (Annual)-20.01%
Gross Margin (Annual)66.17%
Net Profit Margin (5Y Avg)-31.88%
Cash / Share (Quarterly)$1.00
Revenue Growth QoQ (YoY)21.48%
ROA (Last FY)-12.08%
Revenue Growth TTM (YoY)15.00%
EBITD / Share (TTM)$-0.08
ROE (5Y Avg)-81.41%
Operating Margin (TTM)-9.80%
Cash Flow / Share (Annual)$-0.46
P/B Ratio5.64x
P/B Ratio (Quarterly)3.24x
Net Income / Employee (Annual)$-197,100
EV / Revenue (TTM)2.66x
Net Interest Coverage (TTM)-2.55x
ROA (TTM)-10.88%
EV / EBITDA (TTM)80.93x
EPS Incl Extra (Annual)$-0.47
Current Ratio (Annual)1.79x
Quick Ratio (Quarterly)1.38x
3-Month Avg Trading Volume0.22M
52-Week Price Return-21.81%
Revenue / Employee (TTM)$1,115,200
Tangible BV / Share (Quarterly)$0.16
P/S Ratio (Annual)2.81x
Asset Turnover (Annual)0.65x
52-Week High$9.55
Operating Margin (5Y Avg)-26.16%
EPS Excl Extra (Annual)$-0.47
CapEx CAGR (5Y)44.27%
26-Week Price Return-16.31%
Quick Ratio (Annual)1.44x
13-Week Price Return-27.55%
Total Debt / Equity (Annual)0.79x
Current Ratio (Quarterly)1.72x
Enterprise Value$171.90M
Revenue / Share Growth (5Y)-1.39%
Asset Turnover (TTM)0.73x
Revenue / Employee (Annual)$1,066,500
Inventory Turnover (Annual)1.74x
Pretax Margin (Annual)-18.38%
Cash / Share (Annual)$0.89
3-Month Return Std Dev89.38%
Gross Margin (5Y Avg)59.32%
Net Income / Employee (TTM)$-165,300
ROE (Last FY)-35.89%
Net Interest Coverage (Annual)-1.99x
EPS Basic Excl Extra (Annual)$-0.47
P/FCF (TTM)59.73x
Receivables Turnover (TTM)3.01x
Total Debt / Equity (Quarterly)0.82x
EPS Incl Extra (TTM)$-0.38
Receivables Turnover (Annual)3.09x
ROI (TTM)-18.37%
P/S Ratio (TTM)2.69x
Pretax Margin (5Y Avg)-31.25%
Revenue / Share (Annual)$2.52
Tangible BV / Share (Annual)$0.16
Forward P/E13.53x
Price vs S&P 500 (52W)-50.02%
Year-to-Date Return-18.16%
5-Day Price Return5.87%
EPS Normalized (Annual)$-0.47
ROA (5Y Avg)-21.75%
Net Profit Margin (Annual)-18.48%
Month-to-Date Return22.52%
Cash Flow / Share (TTM)$0.07
EBITD / Share (Annual)$-0.16
Operating Margin (Annual)-13.21%
LT Debt / Equity (Annual)0.79x
ROI (5Y Avg)-43.38%
LT Debt / Equity (Quarterly)0.74x
EPS Basic Excl Extra (TTM)$-0.38
P/TBV (Quarterly)22.99x
P/B Ratio (Annual)6.57x
Inventory Turnover (TTM)2.05x
Pretax Margin (TTM)-14.73%
Book Value / Share (Annual)$1.17
Price vs S&P 500 (13W)-37.30%
Beta1.09x
P/FCF (Annual)723.93x
Revenue / Share (TTM)$2.37
ROE (TTM)-35.57%
52-Week Low$4.31
vGradeD
gGradeB
mGradeD
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.08est. -0.08
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.10
4.10
4.10
4.10
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DERMJourney Medical Corporation Common Stock | D | B | D | $6.09 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Journey Medical Corp commercializes a portfolio of eight FDA-approved prescription drugs for dermatological conditions in the U.S. market. Key products include Qbrexza, Accutane, Amzeeq, and Exelderm, which treat various skin-related medical conditions. The company focuses on dermatological treatments for healthcare providers and patients.